Top M&A Of 2016: Cast Your Vote!
It's time once again for In Vivo's Deal of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
In Vivo's Top M&A Of 2016 – The Nominees Are
A Big Year For NASH: Allergan built anon-alcoholic steatohepatitis franchise overnight in mid-September, acquiring Tobira Therapeutics for $1.7 billion and Akarna Therapeutics for $50 million. In April, Gilead Sciences paid $400 million up front plus earn-outs for its fourth NASH project, Nimbus Apollo and its Phase II-ready ACC inhibitor for NASH. [See Deal][See Deal]
LabCorp Strengthens Women's Health Offering With Sequenom Buy: In July,LabCorp of America announced its intent to acquire noninvasive prenatal testing specialist Sequenom in an all-cash deal. The transaction enables LabCorp to broaden its test offerings in women's health and expand its geographic reach, among other things. [See Deal]
Pfizer Prevails In Medivation Bidding War: In the biggest pharma M&A deal of the year to date, Pfizer bested multiple competitors with a $14 billion in August bid for the prostate cancer drug developer, showing just how far big pharmas are willing to go to compete in oncology. [See Deal]
Abbott Buys St. Jude For $25 billion: This April deal was the biggest medtech acquisition of the year, and created huge consolidation in the cardiovascular device market. [See Deal]
QuintilesIMS: Big Merger In Big Data: CRO Quintiles merged with health care data giant IMS Health in May in a deal worth $9 billion. QuintilesIMS will have a market cap close to $18 billion, not to mention a huge head start in finding real-world evidence solutions for clients.